{"disease":{"id":"pheochromocytoma","name":"Pheochromocytoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":5},"drugs":{"marketed":[{"drug_id":"belzutifan","indication_name":"Pheochromocytoma or Paraganglioma (PPGL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Welireg","generic_name":"BELZUTIFAN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"HIF-2α","drug_class":"Hypoxia-inducible Factor Inhibitor [EPC]","quality_score":75,"revenue":"509","mechanism":"Belzutifan inhibits HIF-2α, blocking its interaction with HIF-1β to reduce expression of genes linked to tumor growth."},{"drug_id":"metirosine","indication_name":"Management of inoperable pheochromocytoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Demser","generic_name":"metirosine","company_name":"Aton Pharma Vpna","drug_phase":"marketed","molecular_target":"Tyrosine 3-monooxygenase","drug_class":"Catecholamine Synthesis Inhibitor [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"metirosine","indication_name":"Chronic treatment of malignant pheochromocytoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Demser","generic_name":"metirosine","company_name":"Aton Pharma Vpna","drug_phase":"marketed","molecular_target":"Tyrosine 3-monooxygenase","drug_class":"Catecholamine Synthesis Inhibitor [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"metyrosine","indication_name":"Chronic treatment of malignant pheochromocytoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"METYROSINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Catecholamine Synthesis Inhibitor [EPC]","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"phenoxybenzamine-hydrochloride","indication_name":"Pheochromocytoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PHENOXYBENZAMINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic pheochromocytoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azedra","indication_name":"Pheochromocytoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Azedra","company_name":"David Bushnell","drug_phase":"discontinued","molecular_target":"Sodium-dependent noradrenaline transporter","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"metirosine","indication_name":"Pheochromocytoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Demser","generic_name":"metirosine","company_name":"Aton Pharma Vpna","drug_phase":"marketed","molecular_target":"Tyrosine 3-monooxygenase","drug_class":"Catecholamine Synthesis Inhibitor [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"metirosine","indication_name":"Preoperative preparation for pheochromocytoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Demser","generic_name":"metirosine","company_name":"Aton Pharma Vpna","drug_phase":"marketed","molecular_target":"Tyrosine 3-monooxygenase","drug_class":"Catecholamine Synthesis Inhibitor [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"propranolol","indication_name":"Pheochromocytoma Adjunct Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inderal","generic_name":"propranolol","company_name":"Generic (originally ICI/AstraZeneca)","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2","drug_class":"Non-selective beta-blocker","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":10,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02402244","title":"Project: Every Child for Younger Patients With Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":75000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT06229405","title":"Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data","phase":"","overall_status":"UNKNOWN","enrollment_count":8200,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT00004847","title":"Diagnosis of Pheochromocytoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT03160274","title":"Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"The University of Texas Health Science Center at San Antonio","has_results":false},{"nct_id":"NCT04890444","title":"China Adrenal Disease Registry","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT03474237","title":"A Prospective Cohort Study for Patients With Adrenal Diseases","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1500,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT03050268","title":"Familial Investigations of Childhood Cancer Predisposition","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT04557072","title":"Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection - Systematic Review and Meta-analysis","phase":"","overall_status":"COMPLETED","enrollment_count":1344,"lead_sponsor_name":"Jagiellonian University","has_results":false},{"nct_id":"NCT03344016","title":"Multicenter Pheochromocytoma and Paraganglioma Evaluation","phase":"NA","overall_status":"RECRUITING","enrollment_count":1148,"lead_sponsor_name":"Felix Beuschlein","has_results":false},{"nct_id":"NCT06377033","title":"Using the EHR to Advance Genomic Medicine Across a Diverse Health System","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03583528","title":"DOTATOC PET/CT for Imaging NET Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT06523582","title":"Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Universidad Nacional Autonoma de Mexico","has_results":false},{"nct_id":"NCT07200245","title":"Cardiovascular Complications After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":522,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT07412158","title":"Development and Clinical Application of a Novel Imaging Grading System for Pheochromocytoma and Paraganglioma (PPGL)","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT04788927","title":"Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05446779","title":"Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden Death","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Helsinki University Central Hospital","has_results":false},{"nct_id":"NCT06683846","title":"Ivonescimab in the Treatment of Multiple Advanced Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06573723","title":"Institutional Registry of Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":380,"lead_sponsor_name":"Hospital Italiano de Buenos Aires","has_results":false},{"nct_id":"NCT04924075","title":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":322,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06503146","title":"18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05451134","title":"Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT06870396","title":"National Study of Adrenal Tumours","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":300,"lead_sponsor_name":"Society for Endocrinology","has_results":false},{"nct_id":"NCT05636618","title":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Perspective Therapeutics","has_results":false},{"nct_id":"NCT00126412","title":"Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":251,"lead_sponsor_name":"GE Healthcare","has_results":false},{"nct_id":"NCT06444607","title":"Hereditary Pheochromocytoma Assessment of Tumour Immunologies","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT06669481","title":"Correlation Between Preoperative Images of PPGL and Intraoperative Hemodynamics","phase":"","overall_status":"COMPLETED","enrollment_count":159,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT02721732","title":"Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":157,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT07182175","title":"Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":150,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT04573816","title":"Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma","phase":"","overall_status":"UNKNOWN","enrollment_count":139,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03206060","title":"Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06479811","title":"[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06440122","title":"The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs)","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"King's College Hospital NHS Trust","has_results":false},{"nct_id":"NCT06050057","title":"Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University Hospital Olomouc","has_results":false},{"nct_id":"NCT07167329","title":"Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"José Claudio Casali da Rocha","has_results":false},{"nct_id":"NCT05803330","title":"Study of Alpha-blockers Alone During Preoperative Preparation in Patients With Pheochromocytoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Kunwu Yan,MM","has_results":false},{"nct_id":"NCT04400474","title":"Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Grupo Espanol de Tumores Neuroendocrinos","has_results":true},{"nct_id":"NCT07282587","title":"Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false},{"nct_id":"NCT05053685","title":"Metanephrines in Obstructive Sleep Apnoea","phase":"","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Changi General Hospital","has_results":false},{"nct_id":"NCT01371201","title":"First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT04187404","title":"A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":70,"lead_sponsor_name":"Enterome","has_results":true},{"nct_id":"NCT06427798","title":"Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05858177","title":"The Efficacy and Safety of Temozolomide in Patients With MPPGL","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06062082","title":"Intraoperative Hemodynamic Instability During Unilateral Adrenalectomy for Pheochromocytoma","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT05082311","title":"Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma","phase":"","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","has_results":false},{"nct_id":"NCT04891081","title":"Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"University Medical Centre Ljubljana","has_results":false},{"nct_id":"NCT04394858","title":"Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":46,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06037135","title":"Dexmedetomidine Infusion During Laparoscopic Adrenalectomy","phase":"NA","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT07288931","title":"Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}